Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastrostomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Gastrostomy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-001810-18 Sponsor Protocol Number: 1503 Start Date*: 2007-09-06
    Sponsor Name:University Hospital Of North Staffordshire
    Full Title: Treatment of gastrostomy related granuloma using hydrocortisone or tea tree oil: A randomized controlled trial.
    Medical condition: Granulomas related to gastrostomy sites in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001983-39 Sponsor Protocol Number: PHALS Start Date*: 2017-09-28
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled double blind randomized trial to investigate the efficacy and safety of the combination of Penicillin G / Hydrocortisone treatment in ALS patients (PHALS).
    Medical condition: Patients suffereing from Amytrophic Lateral Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001251-37 Sponsor Protocol Number: 2011-011 Start Date*: 2011-04-20
    Sponsor Name:Vu Medical center
    Full Title: Exploring alternative wound care treatment for percutanous gastrostomy site infection: a prospective, randomized, open, blinded end-point (PROBE) design.
    Medical condition: Infection of the PEG(percutanous endoscopic gastrostomy)-insertion site.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021802 Infection and inflammatory reaction due to unspecified device, implant, and graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017137-22 Sponsor Protocol Number: 190178 Start Date*: 2013-04-16
    Sponsor Name:Klinische Abteilung für Thorax -u. Hyperbare Chirurgie, Medizinische Universität Graz
    Full Title: Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study.
    Medical condition: Patients admitted for treatment on a general thoracic surgery division with the following conditions: Lung cancer Esophageal cancer Cancer of the gastroesophageal junction (GEJ)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004546-15 Sponsor Protocol Number: ZP4207-17106 Start Date*: 2018-08-24
    Sponsor Name:Zealand Pharma A/S
    Full Title: An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
    Medical condition: Children with congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10061211 Hyperinsulinism PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001077-87 Sponsor Protocol Number: IJB-RT-HNC-001 Start Date*: 2019-08-08
    Sponsor Name:Institut Jules Bordet
    Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t...
    Medical condition: advanced head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004184-39 Sponsor Protocol Number: BP39054 Start Date*: 2017-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) DE (Completed) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000095-38 Sponsor Protocol Number: AVXS-101-CL-303 Start Date*: 2020-03-18
    Sponsor Name:AveXis, Inc.
    Full Title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous ...
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000621-12 Sponsor Protocol Number: ISIS396443-CS3A Start Date*: 2017-02-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000782-36 Sponsor Protocol Number: AGO/2013/002 Start Date*: 2013-08-13
    Sponsor Name:Ghent University Hospital
    Full Title: Effect of TachoSil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer.
    Medical condition: Patients with prostate cancer or bladder cancer, undergoing transperitoneal pelvic lymph node dissection.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10057890 Lymph node dissection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002053-19 Sponsor Protocol Number: CLMI070X2201 Start Date*: 2014-12-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Ongoing) CZ (Completed) PL (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002163-34 Sponsor Protocol Number: TopROC Start Date*: 2017-11-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC)
    Medical condition: squamous cell carcinoma of the oropharynx
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026184 Malignant neoplasm of oropharynx LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001780-30 Sponsor Protocol Number: GORTEC 2006-01 Start Date*: 2007-02-28
    Sponsor Name:UCL Saint Luc 1200 Bruxelles
    Full Title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique
    Medical condition: Cet essai s'adresse à des patients porteurs d'un carcinome épidermoïde de la tête et du cou en rechute locale ou en situation métastatique et qui ne peuvent plus bénéficier d'un traitement curatif
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001605-24 Sponsor Protocol Number: GWND19002 Start Date*: 2020-01-15
    Sponsor Name:GW Research Ltd
    Full Title: An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome
    Medical condition: Rett syndrome (RTT) [typical or atypical]
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077709 Rett syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-001534-13 Sponsor Protocol Number: JAN13004-30 Start Date*: 2015-10-02
    Sponsor Name:SPHERIUM BIOMED S.L.
    Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation.
    Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10037763 Radiation mucositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003767-23 Sponsor Protocol Number: EGF105884 Start Date*: 2006-07-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in S...
    Medical condition: Stage III, IVa, IVb Squamous Cell Carcinoma of the Head & Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001506-29 Sponsor Protocol Number: ML 18729 Start Date*: 2005-10-10
    Sponsor Name:Group of Clinical Investigation in Radiotherapy Oncology (GICOR)
    Full Title: PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Ensayo Fase I/II de Erlotinib en combinación con radio...
    Medical condition: PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Disease: Version SOC Term Classification Code Term Level
    PT 10014987 7.1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004723-37 Sponsor Protocol Number: ONO-2506POE015 Start Date*: 2008-05-16
    Sponsor Name:ONO Pharmaceutical Co., Ltd.
    Full Title: A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001816-25 Sponsor Protocol Number: NIR-OGT-201 Start Date*: 2022-12-07
    Sponsor Name:SpringWorks Therapeutics, Inc.
    Full Title: A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa Cell Tumors
    Medical condition: Ovarian Granulosa Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073260 Ovarian granulosa cell tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073273 Ovarian granulosa cell tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000381-29 Sponsor Protocol Number: SCY-078-301 Start Date*: 2017-07-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI)
    Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 07:05:19 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA